TY - JOUR
T1 - The effect of intracamerally injected ethacrynic acid on intraocular pressure in patients with glaucoma
AU - Melamed, S.
AU - Kotas-Neumann, R.
AU - Barak, A.
AU - Epstein, D. L.
N1 - Funding Information:
From the Goldschleger Eye Institute, Tel Aviv University, Sackler Faculty of Medicine, Sheba Medical Center, Tel Hashomer, Israel (Drs. Melamed, Kotas-Neumann, and Barak); and the Glaucoma Service, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts (Dr. Epstein). Dr.Epstein hasa proprietary interest inthedevelopment ofethacrynic acidand derivatives for the treatment of ocular hypertension and glaucoma through relevant patents (US No. 4757089) and patent applications that were developed under research grant EYO 1984 from the National Eye Institute, and were assigned, according to the National Institutes of Health directives, to the Massachusetts Eye and Ear Infirmary.
PY - 1992
Y1 - 1992
N2 - We studied the effect of ethacrynic acid on intraocular pressure in eyes with advanced open-angle glaucoma. Five to 15 μl of ethacrynic acid (3.3 to 9.8 μg) was injected intracamerally after retrobulbar anesthesia was achieved in five eyes of five patients with advanced glaucoma. Intraocular pressure before treatment ranged from 26 to 46 mm Hg with maximal medical treatment. A reduction in intraocular pressure from 9 to 31 mm Hg was observed in all patients three to 24 hours after treatment, and this effect lasted for three days, with a gradual return of intraocular pressure to pretreatment values one week after treatment. No acute corneal or anterior chamber side effects were observed and results of corneal endothelial cell counts were essentially unchanged two months after treatment. We suggest that ethacrynic acid may represent a new class of antiglaucoma medication. Intracameral administration of ethacrynic acid or a derivative might be contemplated in the future at the time of other ocular surgical procedures to treat short-term intraocular pressure increase.
AB - We studied the effect of ethacrynic acid on intraocular pressure in eyes with advanced open-angle glaucoma. Five to 15 μl of ethacrynic acid (3.3 to 9.8 μg) was injected intracamerally after retrobulbar anesthesia was achieved in five eyes of five patients with advanced glaucoma. Intraocular pressure before treatment ranged from 26 to 46 mm Hg with maximal medical treatment. A reduction in intraocular pressure from 9 to 31 mm Hg was observed in all patients three to 24 hours after treatment, and this effect lasted for three days, with a gradual return of intraocular pressure to pretreatment values one week after treatment. No acute corneal or anterior chamber side effects were observed and results of corneal endothelial cell counts were essentially unchanged two months after treatment. We suggest that ethacrynic acid may represent a new class of antiglaucoma medication. Intracameral administration of ethacrynic acid or a derivative might be contemplated in the future at the time of other ocular surgical procedures to treat short-term intraocular pressure increase.
UR - http://www.scopus.com/inward/record.url?scp=0026665828&partnerID=8YFLogxK
U2 - 10.1016/S0002-9394(14)74721-X
DO - 10.1016/S0002-9394(14)74721-X
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:0026665828
SN - 0002-9394
VL - 113
SP - 508
EP - 512
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
IS - 5
ER -